Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781160 | 0.84 | GAA (0.67) | GAARAB9AKMT2AMEN1TDP1 | |
| SCHEMBL6455377 | 0.82 | RAB9A (0.74) | GAARAB9AKMT2AMEN1TDP1 | |
| SCHEMBL5213935 | 0.82 | GAA (0.62) | GAARAB9AKMT2AMEN1TDP1 | |
| SCHEMBL8730078 | 0.81 | TDP1 (0.65) | GAARAB9AKMT2AMEN1TDP1 | |
| SCHEMBL8560540 | 0.79 | GAA (0.62) | GAARAB9AKMT2AMEN1TDP1 | |
| SCHEMBL8730084 | 0.79 | TDP1 (0.70) | GAARAB9AKMT2AMEN1TDP1 | |
| SCHEMBL8242559 | 0.79 | TDP1 (0.45) | GAARAB9ATDP1ALDH1A1HTT | |
| SCHEMBL2763118 | 0.77 | TDP1 (0.56) | GAARAB9ATDP1ALDH1A1MAPK8 | |
| SCHEMBL17863855 | 0.76 | NPC1 (0.57) | GAAKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL26054582 | 0.76 | CTNNB1 (0.47) | GAARAB9AKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | GAA 1769/4885RAB9A 3080/4885KMT2A 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.